Furthermore, this study showed the effect of different ERα+/ERα− ratios on VEGF and TGF-β expression, which would guide the use of VEGFR or TGF-β inhibitors in the treatment of patients with breast cancer who have different ERα+/ERα− ratios. This evidence concerns the gene VEGFA and breast carcinoma.